S. M. Langan-Fahey

发表

Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.

S. Robinson, DelindaA . Johnson, V. Jordan, 1991, Drug metabolism and disposition: the biological fate of chemicals.

Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.

V. Jordan, S. Langan-Fahey, R. Mccague, 1992, Molecular endocrinology.

Human recombinant interferon-βSER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse

E. Borden, DelindaA . Johnson, V. Jordan, 2004, Breast Cancer Research and Treatment.

Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.

S. Robinson, V. Jordan, S. Langan-Fahey, 1989, European journal of cancer & clinical oncology.

Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse.

D. Wolf, V. Jordan, S. Langan-Fahey, 1991, British Journal of Cancer.

Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.

V. Jordan, S. Langan-Fahey, D. Tormey, 1990, European journal of cancer.

Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent.

V. Jordan, S. Langan-Fahey, D. Tormey, 1991, Journal of the National Cancer Institute.

Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells

V. Jordan, S. Langan-Fahey, M. Jeng, 1993 .

Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy.

V. Jordan, V. Jordan, M. Lababidi, 1991, Journal of the National Cancer Institute.

Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.

D. Wolf, V. Jordan, S. Langan-Fahey, 1993, Journal of the National Cancer Institute.

Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.

V. Jordan, S. Langan-Fahey, R. Mccague, 1990, Molecular pharmacology.

The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model

W. Wolberg, V. Jordan, DelindaA . Johnson, 2004, Breast Cancer Research and Treatment.